Therapeutic inhibitors of platelet aggregation - From aspirin to integrin blockers

Transfusion Medicine and Hemotherapy

Volumn 34, Issue 1, 2007, Pages 44-54

  Ahrens, I ^a   Schwarz, M ^a   Peter, K ^b   Bode, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

ASS; COX; GPIIb IIIa; Inhibitors of platelet aggregation; Integrin blockers

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOTRAFIBAN; ORBOFIBAN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PRASUGREL; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; SIBRAFIBAN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTOKINASE; TICLOPIDINE; TIROFIBAN; TYKLID; UNCLASSIFIED DRUG; XEMILOFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERMITTENT CLAUDICATION; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; PLASMA PROTEIN BINDING; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK;

EID: 33846612704     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097664     Document Type: Review

References (108)

1. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994;330(18):1287-94.
2. Clarke RJ, Mayo G, Price P, FitzGerald GA: Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325(16):1137-41.
3. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353(9156):900.
4. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(1 suppl):39S-63S.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2(8607):349-60.
6. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R: ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316(7141):1337-43.
7. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA: Platelet activation in unstable coronary disease. N Engl J Med 1986;315(16):983-9.
8. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(7):396-403.
9. Cairns JA, Gent M, Singer J, Finnie KJ, Froggat, GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, et al: Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313(22):1369-75.
10. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319(17):1105-11.
11. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld JW Jr: Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76(1):125-34.
12. Gawaz M, Neumann FJ, Ott I, May A, Schomig A: Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996;94(3):279-85.
13. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308(6921):81-106.
14. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002;324(7329):71-86.
15. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al: Randomised trial of prophylactic daily aspirin in British male doctors. BMJ (Clin Res Ed) 1988;296(6618):313-6.
16. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321(3):129-35.
17. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268(10):1292-300.
18. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352(13):1293-304.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62.
20. The Medical Research Council's General Practice Research Framework: Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351(9098):233-41.
21. Avanzini F, Palumbo G, Alli C, Roncaglioni MC, Ronchi E, Cristofari M, Capra A, Rossi S, Nosotti L, Costantini C, Pietrofeso R: Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP) - hypertension study. Am J Hypertens 2000;13(6 Pt 1):611-6.
22. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35(3):219-26.
23. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):234S-264S.
24. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75(4):725-48.
25. Soderling SH, Bayuga SJ, Beavo JA: Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998;273(25):15553-8.
26. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH: Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 1995;269(2 Pt 2):H473-9.
27. Arch JR, Newsholme EA: The control of the metabolism and the hormonal role of adenosine. Essays Biochem 1978;14:82-123.
28. Moncada S, Korbut R: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978;i(8077):1286-9.
29. Neri Serneri GG, Masotti G, Poggesi L, Galanti G, Morettini A: Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 1981;21(1):9-15.
30. Schror K: The pharmacology of cilostazol. Diabetes Obes Metab 2002;4(suppl 2):S14-9.
31. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18(12):1942-7.
32. Thompson PD, Zimet R, Forbes WP, Zhang P: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90(12):1314-9.
33. The Persantine-Aspirin Reinfarction Study Research Group: Persantine and aspirin in coronary heart disease. Circulation 1980;62(3):449-61.
34. Klimt CR, Knatterud GL, Stamler J, Meier P: Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7(2):251-69.
35. Sanz G, Pajaron A, Alegria E, Coello I, Cardona M, Fournier JA, Gomez-Recio M, Ruano J, Hidalgo R, Medina A, et al: Prevention of early aorto-coronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC). Circulation 1990;82(3):765-73.
36. Kohler TR, Kaufman JL, Kacoyanis G, Clowes A, Donaldson MC, Kelly E, Skillman J, Couch NP, Whittemore AD, Mannick JA, et al: Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984;96(3):462-6.
37. Stein PD, Collins JJ Jr, Kantrowitz A: Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 1986;89(2 suppl):46S-53S.
38. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1997;51(suppl):S1-77.
39. Sacco RL, Sivenius J, Diener HC: Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005;62(3):403-8.
40. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37(2):577-617.
41. De Schryver EL: Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke 2003;34(10):2339-42.
42. Kimura Y, Tani T, Kanbe T, Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35(7A):1144-9.
43. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H: Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988;36(5):313-20.
44. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20(6):900-6.
45. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM: Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84(5):891-6.
46. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409(6817):202-7.
47. Thebaul JJ, Blatrix CE, Blanchard JF, Panak EA: Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 1975;18(4):485-90.
48. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-39.
49. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342(24):1773-7.
50. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102(6):624-9.
51. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39(1):9-14.
52. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334(17):1084-9.
53. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses JW: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99(18):2364-6.
54. Cosmi B, Rubboli A, Castelvetri C, Milandri M: Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001(4):CD002133.
55. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
56. Gachet C: ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86(1):222-32.
57. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(suppl 2):15-9.
58. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, Ten Berg JM, Neumann FJ, Bollwein H, Dirschinger J, Schomig A: Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004;44(11):2133-6.
59. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig, A: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112(19):2946-50.
60. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48(5):931-8.
61. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K: Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001;52(3):333-6.
62. Storey RF: The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001;12(4):197-209.
63. Fugate SE, Cudd LA: Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 2006;40(5):925-30.
64. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E: Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152(4):627-35.
65. Shattil SJ: Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost 1999;82(2):318-25.
66. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C: Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998;92(9):3240-9.
67. Tcheng JE: Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139(2 Pt 2):S38-45.
68. Lin EC, Ratnikov BI, Tsai PM, Carron CP, Myers DM, Barbas CF III, Smith JW: Identification of a region in the integrin beta3 subunit that confers ligand binding specificity. J Biol Chem 1997;272(38):23912-20.
69. Basani RB, French DL, Vilaire G, Brown DL, Chen F, Coller BS, Derrick JM, Gartner TK, Bennett JS, Poncz M: A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3. Blood 2000;95(1):180-8.
70. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R: Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989;80(6):1766-74.
71. Scarborough RM, Kleiman NS, Phillips DR: Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100(4):437-44.
72. Tam SH, Sassoli PM, Jordan RE, Nakada MT: Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98(11):1085-91.
73. Coller BS: Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 1999;82(2):326-36.
74. Schwarz M, Nordt T, Bode C, Peter K: The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res 2002;107(3-4):121-8.
75. Peter K, Schwarz M, Conradt C, Nordt T, Moser M, Kubler W, Bode C: Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation 1999;100(14):1533-9.
76. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ: Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications Trial. Am J Cardiol 1995;75(8):559-62.
77. Ammar T, Scudder LE, Coller BS: In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95(3):614-7.
78. Marzilli M, Sambuceti G, Testa R, Fedele S: Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol 2002;40(12):2102-9.
79. Simoons ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357(9272):1915-24.
80. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90(4):1757-64.
81. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103(21):2572-8.
82. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295(13):1531-8.
83. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97(17):1680-8.
84. Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kubler W, Bode C: Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000;102(13):1490-6.
85. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE: Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95(4):809-13.
86. Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ: Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999;94(2):587-99.
87. Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kubler W, Bode C: Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999;84(5):519-24.
88. Phillips DR, Scarborough RM: Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(4A):11B-20B.
89. Thibault G, Tardif P, Lapalme G: Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists. J Pharmacol Exp Ther 2001;296(3):690-6.
90. Lele M, Sajid M, Wajih N, Stouffer GA: Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v) beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001;104(5):582-7.
91. The IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349(9063):1422-8.
92. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96(5):1488-94.
93. Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ: Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 2001;88(10):1097-102.
94. The PURSUIT Trial Investigators: Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. N Engl J Med 1998;339(7):436-443.
95. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM: Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006;47(12):2374-9.
96. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356(9247):2037-44.
97. Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleiman NS, Talley D, Aguirre F, Davidson C, Runyon J, Tcheng JE: Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104(4):406-11.
98. Egbertson MS, Chang CT, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ Jr, Lynch RJ, Manno PD, et al: Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37(16):2537-51.
99. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96(5):1445-53.
100. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA: Randomized Comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Circulation 2002;106(12):1470-6.
101. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344(25):1888-94.
102. Smit JJ, Ernst NM, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JC, Dambrink JH, Ottervanger JP, Gosselink AT, de Boer MJ, van't Hof AW: Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. Am Heart J 2006;151(5):1102-7.
103. Chew DP, Bhatt DL, Sapp S, Topol EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103(2):201-6.
104. Coller BS: Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86(1):427-43.
105. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ: Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140(2):206-11.
106. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF: Integrin {alpha}IIb{beta}3 and Its Antagonism. Arterioscler Thromb Vasc Biol 2003;23(6):945-952.
107. Schwarz M, Rottgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Buttner C, Little M, Bode C, Peter K: Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J 2004;18(14):1704-6.
108. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K: Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006;99(1):25-33.